Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com Research for Life
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com
Georg-Speyer-Haus. Foto: Andreas Reeg, andreasreeg.com

Internationale Fellowships to be granted

Within the Innovative Training Network INTERCEPT-MDS, 12 PhD fellowships are available to develop Europe’s first experts in the research field of disease prevention. Click here to access the application portal with application guidelines, full details of the PhD fellowships, projects and eligibility requirements. Read more -> 

Dr. Medyouf participates in EU ITN INTERCEPT-MDS

The research focus of the EU-funded INTERCEPT-MDS project is on myeloid blood cancers and the latest methods of single cell technology to develop innovative research tools for the identification of clonally different cells. In addition, the network unites European expertise in epigenetics and chromatin regulation to specifically identify diseased cells. In doing so, the clinical treatment of diseased cells could be improved in the future using methods of interceptive medicine. Read more ->

New EU research consortium with participation of GSH

The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years, is a collaboration of 22 institutions and pharmaceutical companies. At GSH, active ingredients are to be tested in patient-derived assays. Read more ->

Langener Science Award for Prof. Dr. Krause for research on the bone marrow microenvironment

Friday, Nov 15, 2019, Prof. Dr. Daniela Krause received the Langener Science Award at the Paul-Ehrlich-Institute for her work on Home is where the bone is – The bone marrow as an innovative therapeutic approach to blood formation. “We are pleased to honour Prof. Daniela Krause, a scientist who is researching innovative therapeutic approaches and is instrumental in preparing for their rapid testing in clinical trials,” added Prof. Klaus Cichutek, President of PEI. Read more ->

Page 1 of 4.

1 2 3 4

Apply for International PhD Fellowships

ITN INTERCEPT-MDS announces 12 international PhD fellowships to train Europe’s first experts in the emerging field of disease interception.   Apply Now - 12 positions at the forefront of research into myeloid diseases are open for applications as part of the Innovative Training Network INTERCEPT-MDS - Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the… [mehr]

Dr. Medyouf participates in EU ITN INTERCEPT-MDS

Dr. Medyouf participates in the European Innovative Training Network INTERCEPT-MDS focusing on the shared training and research in Myeloid Diseases.   Dr. Medyouf’s team will participate in the European Innovative Training Network (ITN) INTERCEPT-MDS, a Marie Skłodowska Curie Action, funded by the European Commission under H2020 framework programme, and coordinated by Dr. Marcus Buschbeck at… [mehr]

New EU research consortium with participation of GSH

The EUbOPEN consortium (Enabling and Unlocking Biology in the OPEN) aims to generate a comprehensive pharmacological drug library and make it accessible to the research community. The EU project of the Innovative Medicines Initiative (IMI2), which is funded for 5 years, is a collaboration of 22 institutions and pharmaceutical companies. At GSH, active ingredients are… [mehr]

Beug Foundation Research Award for Dr. Sevenich on metastasis research

This year's 2019 Beug Foundation Metastasis Research Award goes to Dr. Lisa Sevenich for her efforts in studying T-cell responses in brain metastases. "I am very honored by this award. The grant from the Beug Foundation will allow us to study new types of aspects of the complex interactions between tumor cells and immune cells… [mehr]

Prof. Dr. Krause receives project funding from EKFS

Else Kroener-Fresenius-Foundation funds research project of Prof. Dr. Daniela Krause The main focus of the research group headed by Prof. Dr. Daniela Krause is the extracellular matrix in the bone marrow to improve normal and inhibit malignant blood formation. The funding by the EKF Foundation enables the lab unit of Prof. Dr. Krause to investigate… [mehr]

Extention DFG research group for colorectal cancer

Cell Plasticity in Colorectal Carcinogenesis research group under leadership of Prof. Dr. Greten receives extension for additional 3 years   Colorectal cancer is the second leading cause of death among cancers in men and women. Although there have been advancements in diagnosis, therapy in patients with metastases has only been successful in a few patients… [mehr]

Fighting Colorectal Cancer with Killer Cells

Scientists have shown for the 1st time in mini-tumors from the lab that genetically modified defense cells can successfully destroy colon cancer cells. Dabei setzen die Wissenschaftler am GSH auf einen die neue Krebsimmuntherapie mit genmodifizierten natürlichen Killerzellen. Mit den patientenspezifischen Tumorkulturen können Wissenschaftler jetzt im Labor prüfen, wie gut diese bei einzelnen Patienten anschlagen.… [mehr]

Darmkrebs: Unterschiedliche Wnt-Signalwege bringen Darmzellen auf die falsche Bahn

Signalmoleküle der Wnt-Familie gehören zu den wichtigsten Botenstoffen, damit sich unsere stark beanspruchte Darmschleimhaut fortwährend erneuern kann. Gleichzeitig ist ein „Zuviel“ an Wnt ein häufiger Auslöser für Darmkrebs. Wnt gilt deshalb als wichtiger Biomarker und therapeutischer Angriffspunkt. Welche zelluläre Antwort durch Wnt ausgelöst wird, kann dabei einen günstigen oder schlechten Krankheitsverlauf bei Darmkrebspatienten anzeigen. Das zeigten… [mehr]

Ehemalige Direktorin des Georg-Speyer-Hauses erhält in Berlin den Deutschen Zukunftspreis des Bundespräsidenten für Technik und Innovation 2018

Frau Prof. Dr. Helga Rübsamen-Schaeff, Direktorin des Georg-Speyer-Hauses von 1987-1993, erhielt diesen Preis zusammen mit Dr. Holger Zimmermann für die Arbeiten an der von ihr gegründeten Firma AiCuris Anti-infective Cures GmbH, Wuppertal.  Hierbei gelang es den Preisträgern, ein innovatives Medikament gegen ein Virus zu entwickeln und zu vermarkten, das insbesondere bei immunsupprimierten Personen, z.B. nach… [mehr]

Page 1 of 4.

1 2 3 4